Osmotic pressure

CMUH(Taiwan) Using AI to Monitor Home Hemodialysis

Retrieved on: 
Monday, March 18, 2024
Ultrafiltration, Blood pressure, Osmotic pressure, Chronic kidney disease, Renal replacement therapy, Patient, Peritoneal dialysis, Home hemodialysis, Fatigue, AI, Quality of life, Dehydration, Water, Safety, Dialysis, Patient safety, Family, HHD, Work, Medical device

TAICHUNG, March 18, 2024 /PRNewswire/ -- Chronic Kidney Disease has become a new "national disease" in Taiwan, and the number of patients requiring hemodialysis is increasing. Traditionally, hemodialysis patients and accompanies require at least an hour spent on commuting, and that maybe even more time consuming for those who live in suburbs. Moreover, patients almost feel tired or fatigue and need rest half a day following hemodialysis. Since 2019 in Taiwan, China Medical University Hospital (CMUH) has initiated and implemented AI monitoring system for hemodialysis patients. The unique AI system receives the messages sent by the dialysis machine to keep track of any risk message with incorporated AI system, ensuring patient safety and collecting information for prescription adaptation. Accredited with CMUH's AI technology, those who require hemodialysis are not necessary to visit a healthcare facility for this routine. Dr. Huey-Liang Kuo, Director of Hemodialysis Center at CMUH, stated that patients have been heathier and safer to do hemodialysis at home.

Key Points: 
  • Since 2019 in Taiwan, China Medical University Hospital (CMUH) has initiated and implemented AI monitoring system for hemodialysis patients.
  • The unique AI system receives the messages sent by the dialysis machine to keep track of any risk message with incorporated AI system, ensuring patient safety and collecting information for prescription adaptation.
  • Accredited with CMUH's AI technology, those who require hemodialysis are not necessary to visit a healthcare facility for this routine.
  • Dr. Huey-Liang Kuo, Director of Hemodialysis Center at CMUH, stated that patients have been heathier and safer to do hemodialysis at home.

Osmolality Analysis in Bioprocessing: From Theory to Practice, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, November 6, 2023
Molality, Osmotic pressure, Glycoprotein, Cell, Horizon Fuel Cell Technologies, PAT, Glycosylation, Growth, A-DNA, QC, Immunoglobulin G, Buffer, CHO, Fine chemical, Medical imaging

TORONTO, Nov. 6, 2023 /PRNewswire-PRWeb/ -- Discover an informative webinar exploring the impact of osmolality in bioprocessing and in correlation with immunoglobulin G (IgG) production. Osmolality is described as the measurement of the contribution of all the dissolved solutes to the osmotic pressure of a solution. In biopharma, osmolality is usually used as a critical quality control (QC) check for cell culture media, buffers and formulated drug products. It is also used as a critical process parameter during upstream cell culture and downstream filtration.

Key Points: 
  • Attendees will learn about using osmolality analysis in Chinese hamster ovary (CHO) cell health studies.
  • The featured speakers will discuss current uses and future potential for osmolality analysis at the upstream and downstream stages of bioprocessing.
  • TORONTO, Nov. 6, 2023 /PRNewswire-PRWeb/ -- Discover an informative webinar exploring the impact of osmolality in bioprocessing and in correlation with immunoglobulin G (IgG) production.
  • Join this webinar to gain insights into osmolality in correlation with IgG production in a media development project.

Global Blood Plasma Derivatives Market Report 2022: Rising Prevalence of Hemophilia Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 8, 2022
Health, Biotechnology, Hormone, Respiration, Salt, Mineral, Hypogammaglobulinemia, Virus, Antibody, Osmotic pressure, Serum, Thermoregulation, Ageing, Plant, Haemophilia, Infection, Factor IX, Protein, Plasma, Muscle, United Nations, Hepatitis B, FBS, Factor VIII, Haemophilia A, DNA, Hospital, Coagulopathy, Nutrient, Vitamin, Bleeding, Incidence, Blood, Joint, Genetic engineering, Molecular biology, VIII, Application, Coagulation, Hepatitis C, Protease, HIV, Trauma, IX, Blood product, Vaccine

The Global Blood Plasma Derivatives Market size is expected to reach $72.5 billion by 2028, rising at a market growth of 9.3% CAGR during the forecast period.

Key Points: 
  • The Global Blood Plasma Derivatives Market size is expected to reach $72.5 billion by 2028, rising at a market growth of 9.3% CAGR during the forecast period.
  • Blood plasma derivatives are specific protein concentrates extracted from plasma using a fractionation technique.
  • In addition, blood plasma derivatives aid in boosting nutrition, regulating body temperature and blood coagulation, maintaining osmotic pressure, improving respiration as well as excretion, and balancing acid-base levels.
  • In hospitals, clinics, diagnostic facilities, and blood transfusion centers, blood plasma derivatives are widely preserved.

Kanazawa University research: The offshoot of cells visualized in real time

Retrieved on: 
Tuesday, November 8, 2022
Rupture disc, Diagnosis, Journal of Extracellular Vesicles, AFM, PH, Microscopy, Kanazawa University, NPC, Seversky SEV-3, Elasticity, Behavior, Disease, Journal, Thermoregulation, Nanoparticle, Drug development, Osmotic pressure, Temperature, Protein, Seminal vesicles, Tissue, DNA, Cell, Research, Erythrocyte deformability, Membrane, Microscope, Extrusion, Tanning (leather), SEV

Small extracellular vesicles (sEVs) are tiny sacs released by cells to deliver chemical messengers to other cells.

Key Points: 
  • Small extracellular vesicles (sEVs) are tiny sacs released by cells to deliver chemical messengers to other cells.
  • A research team led by Richard Wong and Keesiang Lim at Kanazawa University has now used an advanced form of microscopy to elucidate these changes in real time.
  • Thus, research on sEVs for drug development requires a deeper understanding of how stressful environments affect the vesicles' structure.
  • Small extracellular vesicles (sEVs): sEVs are sacs containing chemicals such as proteins, DNA, or metabolites released by cells.

Kanazawa University research: The offshoot of cells visualized in real time

Retrieved on: 
Tuesday, November 8, 2022
Rupture disc, Diagnosis, Sea, Journal of Extracellular Vesicles, Technology, AFM, PH, Microscopy, Kanazawa University, NPC, SEV (company), Elasticity, Behavior, Disease, School, Journal, Thermoregulation, Ministry, Nanoparticle, Humanities, Drug development, Osmotic pressure, Student, University, Culture, Temperature, History, Protein, Seminal vesicles, Tissue, DNA, Medicine, List, Cell, Research, Erythrocyte deformability, Membrane, Microscope, Extrusion, Tanning (leather), Sport, SEV, Science, Education

Small extracellular vesicles (sEVs) are tiny sacs released by cells to deliver chemical messengers to other cells.

Key Points: 
  • Small extracellular vesicles (sEVs) are tiny sacs released by cells to deliver chemical messengers to other cells.
  • A research team led by Richard Wong and Keesiang Lim at Kanazawa University has now used an advanced form of microscopy to elucidate these changes in real time.
  • The University is located on the coast of the Sea of Japan in Kanazawa a city rich in history and culture.
  • Kanazawa University is divided into two main campuses: Kakuma and Takaramachi for its approximately 10,200 students including 600 from overseas.

Angel Yeast Brings Latest Innovative Products and Solutions to FIC 2022

Retrieved on: 
Friday, August 19, 2022
Osmotic pressure, Drink, Food, Industry, Septic shock, Technology, Growth, Soybean, Snack, Peptide, Taste, Biotechnology, Fermentation, Organic acid, Water, FIC, Nutrient, Environmental impact of meat production, Immune system, Beer, Video game, Dietary supplement

GUANGZHOU, China, Aug. 19, 2022 /PRNewswire/ -- Angel Yeast , (SH600298), a globally listed yeast and yeast extract manufacturer, showcased its latest yeast and yeast extract products, health ingredients, and fermentation ingredients alongside its wide range of innovative solutions at FIC 2022 in Guangzhou.

Key Points: 
  • GUANGZHOU, China, Aug. 19, 2022 /PRNewswire/ -- Angel Yeast , (SH600298), a globally listed yeast and yeast extract manufacturer, showcased its latest yeast and yeast extract products, health ingredients, and fermentation ingredients alongside its wide range of innovative solutions at FIC 2022 in Guangzhou.
  • "We are very excited to attend this year's FIC to share our latest offerings with consumers and business partners.
  • At Angel Yeast, we've also stepped up efforts in innovation to make our yeast and biotechnology products better appeal to the changing habits and trends of the market," added Xiao.
  • Products on display at FIC 2022 includes:
    The latest dry yeast products developed by Angel Yeast can be used in various conditions.

Angel Yeast Brings Latest Innovative Products and Solutions to FIC 2022

Retrieved on: 
Friday, August 19, 2022
Multimedia, Osmotic pressure, Drink, Food, Industry, Septic shock, Technology, Growth, Soybean, Snack, Peptide, Taste, Biotechnology, Fermentation, Organic acid, Water, FIC, Nutrient, Environmental impact of meat production, Immune system, Beer, Video game, Dietary supplement

GUANGZHOU, China, Aug. 19, 2022 /PRNewswire/ -- Angel Yeast , (SH600298), a globally listed yeast and yeast extract manufacturer, showcased its latest yeast and yeast extract products, health ingredients, and fermentation ingredients alongside its wide range of innovative solutions at FIC 2022 in Guangzhou.

Key Points: 
  • GUANGZHOU, China, Aug. 19, 2022 /PRNewswire/ -- Angel Yeast , (SH600298), a globally listed yeast and yeast extract manufacturer, showcased its latest yeast and yeast extract products, health ingredients, and fermentation ingredients alongside its wide range of innovative solutions at FIC 2022 in Guangzhou.
  • "We are very excited to attend this year's FIC to share our latest offerings with consumers and business partners.
  • At Angel Yeast, we've also stepped up efforts in innovation to make our yeast and biotechnology products better appeal to the changing habits and trends of the market," added Xiao.
  • Products on display at FIC 2022 includes:
    The latest dry yeast products developed by Angel Yeast can be used in various conditions.

Inside the jellyfish's sting: exploring the micro-architecture of a cellular weapon

Retrieved on: 
Tuesday, June 21, 2022
Doctor of Philosophy, Solution, Time, Water, Stowers Institute for Medical Research, Osmotic pressure, Institute, Nature Communications, Cnidocyte, Human, American Century Companies, Medical research, Gibson, Nature, Organelle, Medicine, Architecture, Thousandth of an inch, Stowers, Multimedia, Life, Microscope, Medical device, Pharmaceutical industry

KANSAS CITY, Mo., June 21, 2022 /PRNewswire/ -- Summertime beachgoers are all too familiar with the painful reality of a jellyfish sting. But how do the stinging cells of jellyfish and their coral and sea anemone cousins actually work? New research from the Stowers Institute for Medical Research unveils a precise operational model for the stinging organelle of the starlet sea anemone, Nematostella vectensis. The study, published online in Nature Communications on June 17, 2022, was led by Ahmet Karabulut, a predoctoral researcher in the lab of Matt Gibson, PhD. Their work involved the application of cutting-edge microscopic imaging technologies along with the development of a biophysical model to enable a comprehensive understanding of a mechanism that has remained elusive for over a century. Insights from the work could lead to beneficial applications in medicine, including the development of microscopic therapeutic delivery devices for humans.

Key Points: 
  • But how do the stinging cells of jellyfish and their coral and sea anemone cousins actually work?
  • Insights from the work could lead to beneficial applications in medicine, including the development of microscopic therapeutic delivery devices for humans.
  • The first phase is the initial, projectile-like discharge and target penetration of a densely coiled thread from the nematocyst capsule.
  • I realized nematocysts partially discharged their threads while the reagent I used simultaneously and instantaneously fixed the samples," said Karabulut.

Global Blood Plasma Derivatives Market Report 2022: A $40.5 Billion Market in 2021 - Industry Trends, Share, Size, Growth, Opportunity and Forecasts to 2027 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 25, 2022
Health, Cardiology, Blood, Osmotic pressure, Immunodeficiency, Hypogammaglobulinemia, Thermoregulation, Haemophilia, Factor IX, Infection, Patient, Government, Hepatitis B, Hepatitis C, IX, Vitamin, COVID-19, Protease, Salt, Industry, Plasma, Awareness, Factor VIII, Immunity, Hospital, Mineral, Respiration, Hormone, Adoption, Coagulopathy, Protein, HIV, CAGR, Pharmaceutical industry, Blood product, Vaccine, Potash, Growth

The "Blood Plasma Derivatives Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Blood Plasma Derivatives Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global blood plasma derivatives market reached a value of US$ 40.5 billion in 2021.
  • How has the global blood plasma derivatives market performed so far and how will it perform in the coming years?
  • What is the structure of the global blood plasma derivatives market and who are the key players?

DGAP-News: AiCuris announces expansion of its collaboration with Lysando with a focus on diabetic foot infections

Retrieved on: 
Friday, October 22, 2021
MSD, Infection, Nitric oxide, Diabetes, Biotechnology, Cell wall, HCMV, Diagnosis, Quality of life, Gram, Absence, CMV, Gram-positive bacteria, Immune system, Human, Virus, Patient, Gram-negative bacteria, Sepsis, Hepatitis B virus, Biofilm, Severe acute respiratory syndrome coronavirus 2, Degenerative disease, Osmotic pressure, HSV, Multiple organ dysfunction syndrome, Letermovir, Amputation, Company, Disease, Transplant, Veterinary medicine, CEO, Inflammation, Chemistry (relationship), German Future Prize, Bone marrow, WHO, Mortality, Hospital, Pathogenic bacteria, Prevalence, Incidence, Drug of last resort, HBV, Pharmaceutical industry, Vaccine, Fine chemical, Antibiotics, Artilysin(R) - a new class of molecules with a novel resistance-breaking mode of action and the potential to replace common antibiotics, Chronic Wounds and Diabetic Foot Infections, Lysando AG, AiCuris Anti-infective Cures AG, ARTILYSIN(R) - A NEW CLASS OF MOLECULES WITH A NOVEL RESISTANCE-BREAKING MODE OF ACTION AND THE POTENTIAL TO REPLACE COMMON ANTIBIOTICS, CHRONIC WOUNDS AND DIABETIC FOOT INFECTIONS, LYSANDO AG, AICURIS ANTI-INFECTIVE CURES AG

As part of the expanded collaboration, both companies are to develop new Artilysin(R)-based drug candidates for the treatment of Gram-negative bacterial bloodstream infections.

Key Points: 
  • As part of the expanded collaboration, both companies are to develop new Artilysin(R)-based drug candidates for the treatment of Gram-negative bacterial bloodstream infections.
  • Of note, in contrast to a systemic treatment, a topical formulation would also be beneficial in terms of antibiotic stewardship considerations.
  • In addition, the specificity of Artilysin(R)s ensures the preservation of the natural healthy human microbiome and impede recolonization of pathogens.
  • Bacterial infection is the likeliest single cause of delayed healing of chronic open wounds by secondary intention such as diabetic foot infections.